11,202,523 Shares in QuidelOrtho Corporation $QDEL Bought by BlackRock Inc.

BlackRock Inc. purchased a new stake in shares of QuidelOrtho Corporation (NASDAQ:QDEL – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 11,202,523 shares of the company’s stock, valued at approximately $196,212,000. BlackRock Inc. owned 0.16% of QuidelOrtho as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Invesco Ltd. boosted its stake in QuidelOrtho by 87.0% in the 3rd quarter. Invesco Ltd. now owns 2,906,763 shares of the company’s stock worth $85,604,000 after purchasing an additional 1,352,503 shares during the period. Rice Hall James & Associates LLC bought a new position in shares of QuidelOrtho during the second quarter worth $18,628,000. Newtyn Management LLC boosted its position in shares of QuidelOrtho by 58.3% during the third quarter. Newtyn Management LLC now owns 2,700,000 shares of the company’s stock worth $79,515,000 after acquiring an additional 994,332 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in QuidelOrtho by 101.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,755,401 shares of the company’s stock valued at $50,134,000 after acquiring an additional 883,077 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. grew its stake in QuidelOrtho by 7.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,832,098 shares of the company’s stock valued at $337,925,000 after acquiring an additional 819,908 shares in the last quarter. 99.00% of the stock is currently owned by hedge funds and other institutional investors.

Get QuidelOrtho alerts:

QuidelOrtho Price Performance

NASDAQ:QDEL opened at $15.32 on Friday. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -0.99 and a beta of 0.68. QuidelOrtho Corporation has a 1 year low of $9.92 and a 1 year high of $35.58. The business has a 50 day simple moving average of $15.91 and a 200-day simple moving average of $16.05. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76.

QuidelOrtho (NASDAQ:QDEL – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.18. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The firm had revenue of $630.90 million during the quarter, compared to analysts’ expectations of $618.72 million. During the same period in the previous year, the company earned $0.12 EPS. The firm’s revenue for the quarter was up 2.8% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Equities analysts forecast that QuidelOrtho Corporation will post 0.75 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on QDEL shares. JPMorgan Chase & Co. lifted their price target on shares of QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a report on Wednesday, July 1st. Wall Street Zen raised shares of QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th. Jefferies Financial Group restated a “hold” rating on shares of QuidelOrtho in a research report on Monday, June 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a report on Friday, July 17th. Finally, Citigroup boosted their target price on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Three research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $13.62.

View Our Latest Stock Report on QDEL

QuidelOrtho Company Profile

(Free Report)

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.

Recommended Stories

• Five stocks we like better than QuidelOrtho
• Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
• SEC Probe Puts Wall Street Leverage Risk Back in Focus
• A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
• Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?

Want to see what other hedge funds are holding QDEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QuidelOrtho Corporation (NASDAQ:QDEL – Free Report).

Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.